Novo Nordisk stock falls after raised forecast fails to change the debate over its obesity business

Skip NavigationMarketsPre-MarketsU.S. MarketsCurrenciesPrediction MarketsCryptocurrencyFutures & CommoditiesBondsFunds & ETFsBusinessEconomyFinanceHealth & ScienceMediaReal EstateEnergyClimateTransportationInvestigationsIndustrialsRetailWealthSportsLifeSmall BusinessInvestingPersonal FinanceFintechFinancial AdvisorsOptions ActionETF StreetBuffett ArchiveEarningsTrader TalkTechCybersecurityAIEnterpriseInternetMediaMobileSocial MediaCNBC Disruptor 50Tech GuidePolitics & PolicyWhite HousePolicyDefenseCongressExpanding OpportunityVideoLatest VideoFull EpisodesLivestreamLive AudioLive TV ScheduleCNBC PodcastsCEO InterviewsCNBC DocumentariesDigital OriginalsWatchlistInvesting ClubTrust PortfolioAnalysisTrade AlertsMeeting VideosHomestretchJim's ColumnsEducationSubscribePROPro NewsJosh BrownMike SantoliCalls of the DayMy PortfolioLivestreamFull EpisodesStock ScreenerMarket ForecastOptions InvestingChart InvestingSubscribeLivestreamMenuMake ItselectUSAINTLLivestreamSearch quotes, news & videosLivestreamWatchlistSIGN INCreate free accountMarketsBusinessInvestingTechPolitics & PolicyVideoWatchlistInvesting ClubPROLivestreamMenu (function() { const userMembershipOnLastVisit = localStorage.getItem("cnbcMeta__cachedUserMembership"); if (!userMembershipOnLastVisit) { // If no user membership is stored, user is likely not logged in. // These users will typically see the banner. return; } const { isPro, isInvestingClubUser } = JSON.parse(userMembershipOnLastVisit); if (!(isPro || isInvestingClubUser)) { // We’re rendering the top banner for users who are not pro or investing club members. return; } // Hide the banner for pro and investing club users. const style = document.createElement("style"); style.id = "top-banner-placeholder-style"; style.innerHTML = "[data-top-banner-placeholder] { display: none; }"; document.head.appendChild(style); })() Health and ScienceNovo Nordisk stock falls after raised forecast fails to change the debate over its obesity businessPublished Wed, Aug 5 20262:11 AM EDTUpdated An Hour AgoElsa OhlenWATCH LIVEKey PointsNovo Nordisk raised its full-year outlook late Tuesday.Analysts said the better-than-expected quarter benefited from rebate adjustments and other temporary factors.Novo also disclosed another disappointing clinical result for next-generation weight-loss drug CagriSema, reinforcing investor questions about the company's longer-term pipeline.In this articleNVONVOLLYFollow your favorite stocksCREATE FREE ACCOUNTNovo Nordisk's quarterly beat and guidance increase did little to resolve Wall Street's biggest concern: whether the Ozempic maker has a convincing path back to sustainable growth as competition from Eli Lilly intensifies.Analysts said the better-than-expected quarter benefited from rebate adjustments and other temporary factors, obesity drug sales were broadly in line with expectations, and oral Wegovy slightly missed forecasts. At the same time, Novo reported another mixed clinical result for next-generation weight-loss drug CagriSema, reinforcing investor questions about the company's longer-term pipeline."Overall nothing to inspire," Citi analysts wrote, while Jefferies said the guidance increase left little room for consensus sales estimates to move higher.The Danish drugmaker hiked its full-year guidance and said it now expects adjusted sales and operating profit to be down 6% to flat at constant exchange rates, an improvement from previous guidance of a decline of between 4% and 12% for both metrics.Copenhagen-listed shares fell as much as 5% in morning trading before paring some losses to trade 3.4% lower. Novo's American depositary receipts fell 6% in after-hours trading Tuesday after the quarterly report was published one day earlier than expected. Stock Chart I